Teladoc (TDOC) Director Mark V. Anquillare Receives RSU Award

What Happened Mark V. Anquillare, a director of Teladoc Health, was granted 37,425 restricted stock units (RSUs) on August 3, 2026. The award is reported as an acquisition at $0.00 because RSUs are a contingent grant (a derivative right) rather than a cash purchase. No shares were sold; this is a compensation award rather than a market transaction.

Key Details

• Transaction date: 2026-08-03 (reported on Form 4 filed 2026-08-04).
• Grant details: 37,425 RSUs; reported acquisition price $0.00 (derivative award, transaction code A).
• Vesting: One-third vests on the first anniversary of the grant; the remainder vests in eight substantially equal quarterly installments thereafter. (Footnotes: each RSU equals a contingent right to one share.)
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: Filed promptly (Aug 4) for the Aug 3 grant; no late filing indicated.

Context RSUs are common equity compensation for executives and directors. They do not represent immediate ownership of shares until vested and settled; they are not purchases or sales and therefore are not direct bullish/sell signals. This filing simply documents the grant and vesting terms.